Key Points
- COO Kaitlin Kestenberg‑Messina sold 10,096 shares on March 9 at an average price of $15.63 for proceeds of $157,800, reducing her stake by 2.12% to 466,600 shares (disclosed in an SEC Form 4).
- Company and market context: ADMA reported quarterly EPS of $0.20 (in line) and revenue of $139.16M with a 28.8% net margin and 37.5% ROE, and analysts have trended toward Buy with an average target price of $32.
ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) COO Kaitlin Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer directly owned 466,600 shares in the company, valued at approximately $7,292,958. This represents a 2.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
ADMA Biologics Trading Up 0.1%
NASDAQ:ADMA opened at $15.83 on Wednesday. ADMA Biologics Inc has a twelve month low of $13.76 and a twelve month high of $25.67. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16. The business has a 50 day moving average price of $16.81 and a two-hundred day moving average price of $16.74. The company has a market cap of $3.77 billion, a P/E ratio of 26.38 and a beta of 0.51.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The company had revenue of $139.16 million during the quarter, compared to analysts' expectations of $139.80 million. During the same period last year, the business earned $0.46 EPS. The business's quarterly revenue was up 18.4% on a year-over-year basis. As a group, analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.
Institutional Trading of ADMA Biologics
A number of large investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC grew its position in shares of ADMA Biologics by 3.9% in the 2nd quarter. Quadrant Capital Group LLC now owns 16,660 shares of the biotechnology company's stock valued at $303,000 after acquiring an additional 629 shares during the period. Lido Advisors LLC raised its holdings in shares of ADMA Biologics by 3.8% in the 4th quarter. Lido Advisors LLC now owns 17,107 shares of the biotechnology company's stock valued at $312,000 after purchasing an additional 629 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in shares of ADMA Biologics by 11.7% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,063 shares of the biotechnology company's stock valued at $117,000 after purchasing an additional 634 shares during the period. Cim LLC lifted its stake in ADMA Biologics by 0.7% in the 3rd quarter. Cim LLC now owns 91,486 shares of the biotechnology company's stock valued at $1,341,000 after purchasing an additional 665 shares during the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in ADMA Biologics by 28.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 700 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have issued reports on the stock. Zacks Research upgraded shares of ADMA Biologics from a "hold" rating to a "strong-buy" rating in a research note on Monday, March 2nd. Weiss Ratings restated a "hold (c)" rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Finally, Wall Street Zen upgraded ADMA Biologics from a "hold" rating to a "buy" rating in a report on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, ADMA Biologics has an average rating of "Buy" and an average target price of $32.00.
Read Our Latest Report on ADMA Biologics
About ADMA Biologics
(
Get Free Report)
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
